Tag Archives: Cost

To Spur Medical Innovation, Make Corporate Cheaters Pay

The past decade has seen a relatively constant rate of newly approved drugs every year. The number has even jumped in the past few years. Yet, despite such encouraging trends, we are actually facing a crisis in drug innovation today.

April 30, 2015

Go Slow On Reference Pricing: Why The Federal Agencies Have It Wrong On Regulations

Despite concerns outlined in our previous post on reference pricing, federal oversight agencies essentially have taken a hands-off approach. First, they announced that for large group and self-insured plans, the Affordable Care Act's (ACA) annual maximum limits on out-of-pocket costs do not...

March 9, 2015

In The Debate About Cost And Efficacy, PCSK9 Inhibitors May Be The Biggest Challenge Yet

The American health care system is far and away the most costly in the world. Health care reform is intended to lower costs, but they are still rising, albeit less steeply than in the past. Moderation is not however the case in the area of specialty pharmacy. The medications to treat Hepatitis...

February 17, 2015

Whose Costs Are Saved When Palliative Care Saves Costs?

Editor’s note: This post is part of a periodic Health Affairs Blog series on palliative care, health policy, and health reform. The series features essays adapted from and drawing on the volume, Meeting the Needs of Older Adults with Serious Illness: Challenges and Opportunities in the Age of...

September 29, 2014

Having A Baby: Media Confusion Over Charges, Costs, And The Benefits Of Insurance

Recent discussion about the Affordable Care Act has intensified the media’s interest in the cost of medical care. While as health services researchers we are perhaps in the best position to provide information on complex health care topics, we may need to improve our ability to distill...

August 6, 2014

An Ounce Of Prevention For The ACA’s Second Open Enrollment

Since recovering from its flawed rollout, the ACA has enjoyed a string of successes. By April, some eight million Americans managed to enroll; for 2015, some reluctant insurers, including the nation’s second largest (United), are jumping into the new ACA Marketplaces; and the New England...

August 4, 2014

The Payment Reform Landscape: Capitation With Quality

When I began this blog series in February, I explained how Catalyst for Payment Reform (CPR) views different payment reform models along a continuum of financial risk. Thus far, we have used this series to explore the evidence behind “upside only” models that give providers the chance for a...

June 6, 2014

Request For Abstracts: Health Affairs Health Care And Medical Innovation Theme Issue

Health Affairs is planning a theme issue on health care and medical innovation in early-2015. The issue will span the fields of medical technology and also cover public policy and private sector innovations that promote improvements in the delivery of care, lower costs, increase efficiency,...

June 5, 2014

The Cost Of A Cure: Medicare’s Role In Treating Hepatitis C

For a patient with hepatitis C, a potentially deadly disease, the prospect of finding a cure with minimal side effects is a really big deal. Also a big deal is the cost of Sovaldi (sofosbuvir), an oral drug approved by the Food and Drug Administration in December 2013 for the treatment of...

June 5, 2014

Making Markets Work In Health Care: What Does That Mean?

Editor's note: See Robert Berenson's post on consolidation and market power in health care, also published today, and watch for more on these subjects in Health Affairs Blog. Health Affairs last week posted a set of papers that represent several perspectives on Provider Consolidation in...

June 3, 2014